Table 1.
Characteristics of Patients at Randomization, by Treatment Group
| Ciprofloxacin (n = 72) | Placebo (n = 72) | P Value | |
|---|---|---|---|
| Demographics | |||
| Age, yr | 69.1 (8.8) | 69.1 (7.4) | 1.000 |
| Weight, kg | 77.4 (16.5) | 77.1 (21.0) | 0.909 |
| Height, m | 1.68 (0.11) | 1.70 (0.09) | 0.295 |
| Body mass index | 27.5 (5.8) | 26.5 (6.0) | 0.312 |
| Sex, M, n (%) | 44 (61.1) | 47 (65.2) | 0.604 |
| Current smoker, n | 24 | 26 | 0.726 |
| Pack-years | 48.7 (3.5) | 43.3 (23.9) | 0.231 |
| Annual exacerbation rate (IQR) | 3 (1–4) | 2 (1–4) | 0.879 |
| Anthonisen criteria | |||
| Type I | 11 | 11 | 0.763 |
| Type II | 15 | 19 | 0.467 |
| Type III | 31 | 32 | 0.859 |
| Examination findings | |||
| FEV1, L | 1.29 (0.52) | 1.38 (0.51) | 0.269 |
| FEV1% predicted | 48.7 (16.5) | 50.0 (14.9) | 0.608 |
| FVC, L | 2.79 (0.89) | 2.91 (0.76) | 0.380 |
| FEV1/FVC | 0.47 (0.14) | 0.48 (0.13) | 0.734 |
| Oxygen saturation, % | 94.8 (2.24) | 95.0 (1.97) | 0.555 |
| Respiration rate | 17.4 (2.7) | 17.8 (2.8) | 0.322 |
| Point-of-care sampling | |||
| CRP | 15.2 (12.2) | 19.9 (16.3) | 0.158 |
| Disease burden questionnaires | |||
| SGRQ total | 53.4 (18.1) | 52.4 (17.2) | 0.732 |
| CAT | 21.1 (8.3) | 19.8 (7.7) | 0.324 |
Definition of abbreviations: CAT = chronic obstructive pulmonary disease assessment test; CRP = C-reactive protein; IQR = interquartile range; SGRQ = St. George’s Respiratory Questionnaire.
Data are shown as mean (SD) unless otherwise noted.